Elan Corporation, plc · Dublin Ireland ·(NYSE: ELN)(Irish: ELA)
Company Description
Phone: +353-1-709-4000
Fax: +353-1-709-4700
View Elan Corporation, plc Locations On A US Map
This link will open in a new window
This link will open in a new window Elan has brains on its mind. The company is focused on the development of pharmaceuticals for neurological and autoimmune diseases, as well as for severe pain and infection. Its product offerings include anti-infectives Maxipime and Azactam and severe chronic pain infusion Prialt. Elan's future fortunes rely largely on the success of beleaguered multiple sclerosis (MS) therapy Tysabri, which it co-developed with Biogen Idec . Elan's pipeline of potential future releases includes drugs for the treatment of Alzheimer's disease and Parkinson's disease. Its Elan Drug Technologies unit provides specialty drug development using its oral time-release technology to improve the delivery of drugs. To read the full description, subscribe now.
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!
Elan Corporation, plc Executives
31 executives listed for Elan Corporation, plc's Dublin, location.
| Title | Name & Bio | Contact |
| Chairman | Kyran McLaughlin | Network |
| CEO and Director | G. Kelly Martin | Network |
| President | Carlos Paya | Network |
Competition
Competitive Landscape for Elan Corporation, plc
Demand often depends on the income of consumers or the profitability of business customers, because many technology products and services are expensive. The profitability of individual companies is driven by their ability to develop and market new products. Large companies often have advantages in access to capital and marketing. Small companies can compete successfully if they have expertise in a particular field of knowledge. The industry is capital-intensive: average annual revenue per worker is nearly $300,000. To read the full description, subscribe now.Top Elan Corporation, plc Competitors
Call Now at 866-464-3202 or Click here for a Free Hoover's Trial!